NLRP3 and fatty liver disease: A different, recently described Nlrp3-specific inhibitor called CY-09 injected daily intraperitoneally in WT mice on a high-fat diet for 14 weeks resulted in less weight gain and hepatic steatosis (hepatic inflammation and fibrosis were not reported) (13).